EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1

Hideki Goto, Takahiro Kumode, Yuko Mishima, Keisuke Kataoka, Yoshiaki Ogawa, Nobuhiro Kanemura, Kazuyuki Shimada, Toshiki Uchida, Yukano Kuroe, Atsuko Kawasaki, Jotaro Sato, Takanori Teshima

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02662-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Hideki Goto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. hidekigt@med.hokudai.ac.jp. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Neoplasm Recurrence, Local, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a global phase I/II study (GO29781; NCT02500407), single-agent mosunetuzumab had a manageable safety profile and induced durable complete responses in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma, including in patients with R/R follicular lymphoma (FL). In this analysis, the efficacy and safety of mosunetuzumab monotherapy were evaluated in an expansion cohort, FLMOON-1, in Japanese patients with R/R FL who had received ≥ 2 prior lines of therapy in a phase I study (JO40295, jRCT2080223801).

Methods

Mosunetuzumab was administered intravenously at the recommended phase II dose (with cycle 1 step-up dosing) for eight cycles or up to 17 cycles, or until disease progression or unacceptable toxicity. The pre-specified primary endpoint was Independent Review Facility (IRF)-assessed complete response rate (CRR; as best overall response). Secondary objectives included investigator (INV)-assessed CRR, INV- and IRF-assessed objective response rate (ORR), and safety.

Results

At the data cutoff (October 13, 2023), 19 patients (median age 72 years) were evaluated. The IRF-assessed CRR and ORR were 68.4% and 78.9%, respectively; the INV-assessed CRR and ORR were 63.2% and 84.2%, respectively. Grade 3–4 adverse events (AEs) were observed in 89.5% of patients, with a low incidence of AEs leading to mosunetuzumab discontinuation (10.5%) and one fatal AE unrelated to mosunetuzumab. Cytokine release syndrome occurred in 47.4% of patients and were mostly Grade 1 in severity.

Conclusion

These findings indicate mosunetuzumab has a consistent efficacy and manageable safety profile in Japanese patients with R/R FL compared with previously reported data from the global phase I/II study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansMaleFemaleAgedMiddle AgedAdultJapanAged, 80 and overDrug Resistance, NeoplasmTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

AdministrationAntibodiesBispecificFollicularIntravenousJapanLymphomaNon-Hodgkin

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan. hidekigt@med.hokudai.ac.jp.
  • Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Hokkaido, Japan. hidekigt@med.hokudai.ac.jp.
  • Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
  • Department of Hematology Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Hematology & Oncology, Tokai University School of Medicine, Kanagawa, Japan.

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Goto, H., Kumode, T., Mishima, Y., Kataoka, K., Ogawa, Y., Kanemura, N., Shimada, K., Uchida, T., Kuroe, Y., Kawasaki, A., Sato, J., & Teshima, T. (2025). Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02662-5

Vancouver

Goto H, Kumode T, Mishima Y, Kataoka K, Ogawa Y, Kanemura N, et al. Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02662-5

BibTeX
@article{Goto2025,
  author = {Goto, Hideki and Kumode, Takahiro and Mishima, Yuko and Kataoka, Keisuke and Ogawa, Yoshiaki and Kanemura, Nobuhiro and Shimada, Kazuyuki and Uchida, Toshiki and Kuroe, Yukano and Kawasaki, Atsuko and Sato, Jotaro and Teshima, Takanori},
  title = {Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02662-5}
}
Kostenlos starten →